Fig. 7
β-catenin acts as a downstream effector of ZDHHC8. (a) Correlation between ZDHHC8 expression and WNT/β-catenin pathway activity48,49,50as determined by ssGSEA. (b) Comparative analysis of β-catenin expression at the mRNA level (qPCR) and protein level (WB) in vehicle- and CDDP-treated HGSOC cells with ZDHHC8 knockdown or overexpression. (c) β-catenin expression level in shKLF5 HGSOC cells following CDDP treatment. (d) Validation of XAV939’s inhibitory effect on β-catenin levels in OVCAR-3 cells. (e) Dose-response curves of CDDP in oeZDHHC8 OVCAR-3 cells, with or without 10 µM XAV939. (f) Flow cytometry analysis of apoptosis in oeZDHHC8 OVCAR-3 cells treated with CDDP, with or without 10 µM XAV939. (g) γ-H2AX immunofluorescence staining showing DNA damage in CDDP-treated oeZDHHC8 OVCAR-3 cells, with or without 10 µM XAV939.
